Thrombomodulin Alfa API Manufacturers

compare suppliers & get competitive offers

teaser-1024x654-1
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Thrombomodulin Alfa is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Thrombomodulin Alfa or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Thrombomodulin Alfa API 120313-91-9?

Description:
Here you will find a list of producers, manufacturers and distributors of Thrombomodulin Alfa. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Thrombomodulin Alfa 
Synonyms:
Thrombomodulin (human 498-amino acid fragment) , Thrombomodulin Alfa  
Cas Number:
120313-91-9 
DrugBank number:
DB05777 
Unique Ingredient Identifier:
2VU8WT49WX

General Description:

Thrombomodulin Alfa, identified by CAS number 120313-91-9, is a notable compound with significant therapeutic applications. Thrombomodulin Alfa is a novel, recombinant and soluble thrombomodulin (ART-123). It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular thromboembolism.

Indications:

This drug is primarily indicated for: Investigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Half-life:

The half-life of Thrombomodulin Alfa is an important consideration for its dosing schedule: 2–3 days after sc injection; 19.82 +/- 2.10 hours after IV injection. This determines the duration of action and helps in formulating effective dosing regimens.

Route of Elimination:

The elimination of Thrombomodulin Alfa from the body primarily occurs through: rapidly eliminated through liver. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Clearance:

The clearance rate of Thrombomodulin Alfa is a critical factor in determining its safe and effective dosage: 7-10 days. It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Thrombomodulin Alfa exerts its therapeutic effects through: Thrombomodulin (TM) alfa, a recombinant human soluble TM, enhances activation of pro-carboxypeptidase B2 (pro-CPB2) by thrombin. Activated pro-CPB2 (CPB2) exerts anti-inflammatory and anti-fibrinolytic activities. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Thrombomodulin Alfa functions by: Thrombomodulin alfa is a soluble form of recombinant human thrombomodulin comprising all extracellular domains of thrombomodulin. Bound to thrombin, Thrombomodulin alfa inhibits its procoagulant activity and promotes activation of protein C. Thrombomodulin alfa inhibits thrombin generation by the activation of protein C and the subsequent inactivation of factor Va in the presence of protein S. Thrombomodulin alfa attenuates the extension of the clot by inhibiting further thrombin generation on clots, while other anticoagulants inhibit the initiation of clot formation. A higher concentration of Thrombomodulin alfa is needed to affect clotting time and platelet aggregation than thrombin generation. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Classification:

Thrombomodulin Alfa belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.

Categories:

Thrombomodulin Alfa is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Glycoproteins, Membrane Glycoproteins, Membrane Proteins, Platelet Membrane Glycoproteins, Proteins, Receptors, Peptide, Receptors, Thrombin. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Thrombomodulin Alfa is a type of Anti-inflammatory Agents


Anti-inflammatory agents are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used to treat various inflammatory conditions. These agents play a vital role in alleviating pain, reducing swelling, and controlling inflammation in the body. They are widely employed in the management of diverse medical conditions, including arthritis, autoimmune disorders, asthma, and skin conditions like dermatitis.

Anti-inflammatory APIs primarily function by inhibiting the production of specific enzymes called cyclooxygenases (COX) and lipoxygenases (LOX). These enzymes are responsible for the synthesis of pro-inflammatory molecules known as prostaglandins and leukotrienes, respectively. By suppressing the activity of COX and LOX, anti-inflammatory agents effectively curtail the production of these inflammatory mediators, thereby mitigating inflammation.

Common examples of anti-inflammatory APIs include non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, aspirin, and naproxen. These agents exhibit analgesic, antipyretic, and anti-inflammatory properties. Another group of anti-inflammatory APIs includes corticosteroids, such as prednisone and dexamethasone, which are synthetic hormones that modulate the body's immune response to control inflammation.

In conclusion, anti-inflammatory agents are a vital category of pharmaceutical APIs widely used to manage inflammation-related disorders. They target enzymes involved in the synthesis of pro-inflammatory molecules, effectively reducing pain and swelling. NSAIDs and corticosteroids are commonly prescribed anti-inflammatory APIs due to their efficacy in controlling inflammation.